Amylyx Pharmaceuticals, Inc. (AMLX)

USD 3.94

(-7.94%)

Market Cap (In USD)

270.07 Million

Revenue (In USD)

380.78 Million

Net Income (In USD)

49.27 Million

Avg. Volume

1.6 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.575-19.949
PE
-
EPS
-
Beta Value
-0.699
ISIN
US03237H1014
CUSIP
03237H101
CIK
1658551
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joshua B. Cohen
Employee Count
-
Website
https://amylyx.com
Ipo Date
2022-01-07
Details
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.